292 related articles for article (PubMed ID: 34158138)
1. Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment.
Asken BM; VandeVrede L; Rojas JC; Fonseca C; Staffaroni AM; Elahi FM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Boxer AL; Miller BL; Rosen HJ; Kramer JH; Casaletto KB
J Int Neuropsychol Soc; 2022 Jul; 28(6):588-599. PubMed ID: 34158138
[TBL] [Abstract][Full Text] [Related]
2. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
3. Combination of plasma amyloid beta
Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
[TBL] [Abstract][Full Text] [Related]
4. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
5. Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study.
Zhang Y; Ferreira PCL; Jacobsen E; Bellaver B; Pascoal TA; Snitz BE; Chang CH; Villemagne VL; Ganguli M; Karikari TK
Alzheimers Dement; 2024 Jun; 20(6):4199-4211. PubMed ID: 38753951
[TBL] [Abstract][Full Text] [Related]
6. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
7. White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study.
Sudre CH; Bocchetta M; Heller C; Convery R; Neason M; Moore KM; Cash DM; Thomas DL; Woollacott IOC; Foiani M; Heslegrave A; Shafei R; Greaves C; van Swieten J; Moreno F; Sanchez-Valle R; Borroni B; Laforce R; Masellis M; Tartaglia MC; Graff C; Galimberti D; Rowe JB; Finger E; Synofzik M; Vandenberghe R; de Mendonça A; Tagliavini F; Santana I; Ducharme S; Butler C; Gerhard A; Levin J; Danek A; Frisoni GB; Sorbi S; Otto M; Zetterberg H; Ourselin S; Cardoso MJ; Rohrer JD;
Neuroimage Clin; 2019; 24():102077. PubMed ID: 31835286
[TBL] [Abstract][Full Text] [Related]
8. Relationship between topological efficiency of white matter structural connectome and plasma biomarkers across the Alzheimer's disease continuum.
Zhang M; Chen H; Huang W; Guo T; Ma G; Han Y; Shu N
Hum Brain Mapp; 2024 Jan; 45(1):e26566. PubMed ID: 38224535
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.
Yang Z; Sreenivasan K; Toledano Strom EN; Osse AML; Pasia LG; Cosme CG; Mugosa MRN; Chevalier EL; Ritter A; Miller JB; Cordes D; Cummings JL; Kinney JW
Alzheimers Res Ther; 2023 Nov; 15(1):190. PubMed ID: 37924152
[TBL] [Abstract][Full Text] [Related]
10. Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men.
Tang R; Buchholz E; Dale AM; Rissman RA; Fennema-Notestine C; Gillespie NA; Hagler DJ; Lyons MJ; Neale MC; Panizzon MS; Puckett OK; Reynolds CA; Franz CE; Kremen WS; Elman JA
Alzheimers Res Ther; 2024 Apr; 16(1):90. PubMed ID: 38664843
[TBL] [Abstract][Full Text] [Related]
11. The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer's disease.
Walsh P; Sudre CH; Fiford CM; Ryan NS; Lashley T; Frost C; Barnes J;
Neurobiol Aging; 2021 Jan; 97():10-17. PubMed ID: 33070094
[TBL] [Abstract][Full Text] [Related]
12. Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies.
Hamilton CA; O'Brien J; Heslegrave A; Laban R; Donaghy P; Durcan R; Lawley S; Barnett N; Roberts G; Firbank M; Taylor JP; Zetterberg H; Thomas A
Psychol Med; 2023 Dec; 53(16):7865-7873. PubMed ID: 37489795
[TBL] [Abstract][Full Text] [Related]
13. Blood biomarkers for dementia in Hispanic and non-Hispanic White adults.
Gonzales MM; Short MI; Satizabal CL; O' Bryant S; Tracy RP; Zare H; Seshadri S
Alzheimers Dement (N Y); 2021; 7(1):e12164. PubMed ID: 33860071
[TBL] [Abstract][Full Text] [Related]
14. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study.
Verberk IMW; Laarhuis MB; van den Bosch KA; Ebenau JL; van Leeuwenstijn M; Prins ND; Scheltens P; Teunissen CE; van der Flier WM
Lancet Healthy Longev; 2021 Feb; 2(2):e87-e95. PubMed ID: 36098162
[TBL] [Abstract][Full Text] [Related]
15. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
16. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment.
Kivisäkk P; Carlyle BC; Sweeney T; Trombetta BA; LaCasse K; El-Mufti L; Tuncali I; Chibnik LB; Das S; Scherzer CR; Johnson KA; Dickerson BC; Gomez-Isla T; Blacker D; Oakley DH; Frosch MP; Hyman BT; Aghvanyan A; Bathala P; Campbell C; Sigal G; Stengelin M; Arnold SE
Front Neurol; 2023; 14():1069411. PubMed ID: 36937522
[TBL] [Abstract][Full Text] [Related]
17. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
18. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment.
Mazzeo S; Ingannato A; Giacomucci G; Bagnoli S; Cavaliere A; Moschini V; Balestrini J; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Padiglioni S; Sorbi S; Nacmias B; Bessi V
Neurol Sci; 2024 Mar; 45(3):1031-1039. PubMed ID: 37723371
[TBL] [Abstract][Full Text] [Related]
19. Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study.
Götze K; Vrillon A; Bouaziz-Amar E; Mouton-Liger F; Hugon J; Martinet M; Dumurgier J; Cognat E; Zetterberg H; Blennow K; Hourrègue C; Paquet C; Lilamand M
Neurobiol Dis; 2023 Jan; 176():105937. PubMed ID: 36462720
[TBL] [Abstract][Full Text] [Related]
20. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
